Journals in Pharmacology

1-10 of 74 results in All results

Advances in Medical Sciences

ISSN: 1896-1126
5 Year impact factor: 2.8
Impact factor: 2.7

Advances in Medical Sciences is an international, peer-reviewed journal that welcomes original research articles and reviews on current advances in life sciences, preclinical and clinical medicine, and related disciplines. The Journal’s primary aim is to make every effort to contribute to progress in medical sciences. The strive is to bridge laboratory and clinical settings with cutting edge research findings and new developments. Advances in Medical Sciences publishes articles which bring novel insights into diagnostic and molecular imaging, offering essential prior knowledge for diagnosis and treatment indispensable in all areas of medical sciences. It also publishes articles on pathological sciences giving foundation knowledge on the overall study of human diseases. Through its publications Advances in Medical Sciences also stresses the importance of pharmaceutical sciences as a rapidly and ever expanding area of research on drug design, development, action and evaluation contributing significantly to a variety of scientific disciplines. The journal welcomes submissions from the following disciplines: General and internal medicine, Cancer research, Genetics, Endocrinology, Gastroenterology, Cardiology and Cardiovascular Medicine, Immunology and Allergy, Pathology and Forensic Medicine, Cell and molecular Biology, Haematology, Biochemistry, Clinical and Experimental Pathology. Only review articles from experts in the field will be considered for publication. The journal does not accept case reports. Please see our Guide for Authors for information on article submission. Benefits to authors We also provide many author benefits, such as free PDFs, special discounts on Elsevier publications and much more. Please click here for more information on our author services. Advances in Medical Sciences, founded in 1955, is the official journal of the Medical University of Bialystok, Poland.

African Journal of Urology

ISSN: 1110-5704

As of 1 January 2019 the journal has been transferred to the new Publisher, Springer Nature.

Alexandria Journal of Medicine

ISSN: 2090-5068

As of 1 January 2019 the journal has been transferred to the new Publisher, Taylor and Francis.The Alexandria Journal of Medicine is concerned with providing a venue for publication of research, with a particular focus on diseases of high prevalence in MENA (Middle East and North Africa) and its comparison to their profile worldwide. Manuscripts from the international scientific community are also welcome to cater to the interests of our broad readership, both regional and worldwide and to increase the opportunities for fruitful interregional scientific collaboration. The journal publishes original research articles, review articles, short communications and clinical trials in an open access format. Furthermore, time to first decision has been set to be within 6 weeks to facilitate rapid dissemination of high quality accepted articles.

Antiviral Research

ISSN: 0166-3542
5 Year impact factor: 5.8
Impact factor: 7.6

Antiviral Research publishes research reports, short communications, review articles and commentaries on the control of viral infections in humans and animals. Its scope encompasses: antiviral drugs, antibodies and host-response modifiers, including their synthesis, in vitro and in vivo testing and mechanisms of action. new or improved vaccines against viral infections of humans; assessments of drug and vaccine safety; evolution of drug- or vaccine-resistant viruses and the development of effective countermeasures; identification and validation of new drug targets; laboratory animal models of viral diseases; pathogenesis of viral diseases and mechanisms of viral evasion of host immune responses. We encourage the submission of manuscripts describing the activity of well-defined chemical compounds for the treatment of viral diseases of humans and vertebrate animals. We also publish manuscripts on the protective activity of vaccines for humans, and we will consider reports of the testing of veterinary vaccines in the target animal species. All papers must include a sufficiently detailed description of methods to permit other investigators to replicate the experiments. Authors reporting the antiviral effect of a novel small-molecule drug must reveal its chemical structure. Claims of in vitro or in vivo efficacy of a drug or vaccine must be supported by appropriate statistical analysis. Note: Antiviral Research may choose not to publish certain COVID-19 papers. The COVID-19 pandemic has focused attention on the possibility that patients infected with SARS-CoV-2 might benefit from treatment with certain licensed drugs approved for conditions other than viral infection. Reports that various medications inhibit the replication of the virus in vitro have been widely publicized in news articles and on medical websites, giving the impression that compounds still in the earliest stage of evaluation may be used to prevent or treat COVID-19. Such misunderstanding may result in the inappropriate use of a drug by physicians and to self-treatment by people who obtain it from other sources, with a risk of toxicity. This may be a particular problem when a medication is available without prescription as a veterinary product. Hoarding or inappropriate use of a drug intended to treat another disease may also make it unavailable to patients with that disease. The editors of Antiviral Research may therefore choose not to publish certain COVID-19 manuscripts, when in our judgment publication is likely to result in harm, without clear evidence of benefit. The scope of AVR also includes the prevention and treatment of viral diseases of vertebrate animals. We do not publish reports on viral diseases of plants or of insects, crustaceans or other invertebrates. Studies of viral diseases of livestock and companion animals must be clearly related to the development of realistic therapies. Papers on veterinary vaccines should report findings in the target animal species. We discourage the submission of manuscripts reporting the antiviral activity of unpurified natural products, or of partially purified substances of natural origin for which a mechanism of action has not been determined. Manuscripts claiming an antiviral effect of homeopathic products or other highly diluted preparations, or which fail to clearly identify the biological ingredient or molecule responsible for the antiviral activity of an experimental therapy, will not be considered for publication. Articles describing antiseptics with broad-spectrum antimicrobial activity will not be accepted. We also discourage submission of in silico docking studies or other computer-based predictions of antiviral activity that are not supported by data from biological assays. Citations of reports that have not undergone peer review must include the note "[not peer-reviewed]." Antiviral Research is an official publication of the International Society for Antiviral Research (http://www.isar-icar.com). Benefits to authors We also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services . Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our Support Center

Artificial Intelligence in the Life Sciences

ISSN: 2667-3185

Providing a scientific forum for practical applications and theoretical advances of Artificial Intelligence (AI) in the life sciences and related disciplines including (but not restricted to): General, molecular, and systems biology Population and disease genetics Medicinal chemistry and chemical biology Pharmacology and drug discovery Epidemiology and clinical investigations Background: Artificial Intelligence originates from computer science and covers a wide range of approaches intended to enhance the ability of machines to make data-driven decisions and accurate predictions of events. In many scientific fields, AI is being increasingly considered and integrated, especially in the context of Big Data. Given their complexity and highly interdisciplinary nature, the life sciences provide ample opportunities for AI to impact R&D efforts in a variety of ways. Key words: Artificial Intelligence; Life Sciences; Drug Discovery; Bio- and Cheminformatics, Machine Learning; Machine Intelligence; Deep Learning; Data Mining; Big Data.

Image - Artificial Intelligence in the Life Sciences

Biochemical Pharmacology

ISSN: 0006-2952
5 Year impact factor: 5.8
Impact factor: 5.8

Biochemical Pharmacology publishes original research findings and review articles related to the elucidation of cellular and tissue function(s) at the biochemical and molecular levels, the modification of cellular phenotype(s) by genetic, transcriptional/translational or drug/compound-induced modifications, as well as the pharmacodynamics and pharmacokinetics of xenobiotics and drugs, the latter including both small molecules and biologics. The journal's target audience includes scientists engaged in the identification and study of the mechanisms of action of xenobiotics, biologics and drugs and in the drug discovery and development process. All areas of cellular biology and cellular, tissue/organ and whole animal pharmacology fall within the scope of the journal. Drug classes covered include anti-infectives, anti-inflammatory agents, chemotherapeutics, cardiovascular, endocrinological, immunological, metabolic, neurological and psychiatric drugs, as well as research on drug metabolism and kinetics. While medicinal chemistry is a topic of complementary interest, manuscripts in this area must contain sufficient biological data to characterize pharmacologically the compounds reported. Submissions describing work focused predominately on chemical synthesis and molecular modeling will not be considered for review. While particular emphasis is placed on reporting the results of molecular and biochemical studies, research involving the use of tissue and animal models of human pathophysiology and toxicology is of interest to the extent that it helps define drug mechanisms of action, safety and efficacy. Reports describing experiments conducted with natural product mixtures, plant or animal extracts will not be considered for publication unless the structures and concentrations of all component substances are known, and the agents can be easily obtained by others wishing to replicate the study. The chemical structure of all novel compounds tested must be included in the submitted manuscript or be readily accessible in the published literature. References to structures in the patent literature must unambiguously identify a single molecular structure. All compounds, reagents, instrumentation and equipment employed in a study must be available from identified commercial suppliers, bio/pharmaceutical companies or from individuals holding legal rights to their use. Submissions will not be considered for publication if the chemical structures of tested compounds are not revealed, generally known, or accessible in the literature. Original research submissions must contain: A rationale for the selection of the compound/drug for study as well as for the concentrations/doses employed. Quantities used for concentration- and dose-response experiments should vary logarithmically, e.g., 1, 3, 10, 30 mg/kg, 0.1, 1.0, 10, 100 nanomolar, etc. Justification must be provided for studying only a single concentration or dose of a compound, especially as it relates to reference standards and antagonists/modulators of receptors, enzymes and signaling pathways. Justification must also be provided for the selection of the statistical tests employed as they relate to the experimental design. It is expected that all findings have been subjected to rigorous quantitative analyses, with the calculation and reporting of IC50, Ki, EC50, etc., values. These must be derived from a minimum of three (3) separate and distinct experiments, with the replicates within any single experiment being averaged to obtain a single value for that experimental series. Manuscripts that fail to meet these criteria will be subject to rejection without peer-review. US National Institutes of Health (NIH) voluntary posting ("Public Access") policy Biochemical Pharmacology and Elsevier facilitate the author's response to the NIH Public Access Policy. Please bookmark this URL: https://www.elsevier.com/locate/biochempharm Benefits to authors We also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services . Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our Support Center

Biomedicine & Pharmacotherapy

ISSN: 0753-3322
5 Year impact factor: 6.8
Impact factor: 7.5

Biomedicine & Pharmacotherapy is a multidisciplinary journal which publishes full-length, original research reports, reviews, and preliminary communications or letters to the editor which fall within the general scope of clinical and basic medicine and pharmacology. The general fields of interest will include Cancer, Nutriceutics, Neurodegenerative, Cardiac and Infectious Diseases. Special emphasis will be placed on studies of specific topics such as molecular mechanisms, gene regulation in normal and pathologic cells as well as susceptibility in response to oncogenic agents. Effects of drugs on preclinical and clinical pharmacology and the role of bacteria, viruses and parasites in animals and humans. Brief reports of meetings, symposia and conferences will also be considered for publication as well as brief listings of scientific meetings or academic courses of interest to the readers

Cellular Signalling

ISSN: 0898-6568
5 Year impact factor: 4.5
Impact factor: 4.8

Cellular Signalling publishes original research describing fundamental and clinical findings on the mechanisms, actions and structural components of cellular signalling systems in vitro and in vivo. Cellular Signalling aims at full length research papers defining signalling systems ranging from microorganisms to cells, tissues and higher organisms. Cellular Signalling strives to offer a fair and fast peer-review process with a single round of revisions. Reviews are by invitation-only. Short Reports are not accepted.

Clinical Microbiology Newsletter

ISSN: 0196-4399

Highly respected for its ability to keep pace with advances in this fast moving field, Clinical Microbiology Newsletter has quickly become a benchmark for anyone in the lab. Twice a month the newsletter reports on changes that affect your work, ranging from articles on new diagnostic techniques, to surveys of how readers handle blood cultures, to editorials questioning common procedures and suggesting new ones. Clinical Microbiology Newsletter brings you: – Minireviews on pathogenesis, diagnosis, epidemiology, therapy of infectious diseases – Practical and brief articles on laboratory techniques – Indispensable updates on important clinical problems – Editorials and opinions on controversial issues in laboratory medicine – Helpful tips on improving the laboratory workplace In these days of cost containment and high expectations, Clinical Microbiology Newsletter can help you streamline procedures and improve results.

Clinical Therapeutics

ISSN: 0149-2918
5 Year impact factor: 3.2
Impact factor: 3.2

Clinical Therapeutics provides peer-reviewed, rapid publication of recent developments in drug and other therapies as well as in diagnostics, pharmacoeconomics, health policy, treatment outcomes, and innovations in drug and biologics research. In addition Clinical Therapeutics features updates on specific topics collated by expert Topic Editors. Clinical Therapeutics is read by a large international audience of scientists and clinicians in a variety of research, academic, and clinical practice settings. Articles are indexed by all major biomedical abstracting databases. Published articles range from pivotal studies exploring new chemical entities in large, multicenter trials to those exploring repurposing of marketed agents. Additionally, pilot studies; reports that assess drug safety and tolera-bility in all phases of development; new routes of administration and new formulations; pharmacokinetic, bio-availability, and biosimilarity; and changes in practice guidelines and standards, are all of interest for publication. Clinical Therapeutics also understands the importance of strengthening the body of evidence surrounding particular agents through the publication of replication studies, negative trials, and failed trials. Beyond the clinic, we seek reports that examine the real-world implications of therapeutics such as comparative effectiveness and pharmacoeconomics studies as well as work that has implications for health policy. Commentaries, which include perspectives and contemporary issues, are sought to offer a balance of viewpoints and scholarly opinion on a broad array of drug-related topics. Case reports, which remain a vital part of our mission, offer clinically valuable lessons. All manuscripts are peer reviewed by independent clinicians or scientists for clinical relevance, technical accuracy, methodological rigor, clarity, and objectivity using a blind review process. In addition to feature articles published monthly, each issue of Clinical Therapeutics features a specific theme section dedicated to an annual update of a specific topic area. A special guest editor will comprise each update with reviews, commentaries, and original research highlighting what's new or controversial in the topical specialty. Authors are invited to submit manuscripts for consideration in the topic updates, identifying submissions as such in their cover letters. Submissions not selected for the updates will be considered for general publication. Submit your manuscript at https://www.editorialmanager.com/clinther.